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Background
In this study, we investigated the effects of reduced-dose craniospinal radiotherapy 
(CSRT) followed by tandem high-dose chemotherapy (HDCT) with autologous stem cell 
rescue (ASCR) in children with a newly diagnosed high-risk medulloblastoma (MB) or 
supratentorial primitive neuroectodermal tumor (sPNET). 
Methods
Between March 2005 and April 2007, patients older than 3 years with a newly diagnosed 
high-risk MB or sPNET were enrolled. The patients received two cycles of pre-RT chemo-
therapy consisting of cisplatin, etoposide, vincristine, and cyclophosphamide (cycle A), 
and carboplatin, etoposide, vincristine, and ifosphamide (cycle B), followed by CSRT with 
23.4 Gy and local RT with 30.6 Gy. After four cycles of post-RT chemotherapy (cycles A, 
B, A, and B), tandem double HDCT with ASCR was performed. 
Results
A total of 13 patients (MB=11, sPNET=2) were enrolled. Of these, one patient progressed, 
one patient died of septic shock after the second cycle of B, and one patient relapsed after 
the third cycle of B. The 3-year event-free survival (EFS) rate of the patients intended for 
HDCT was 76.9%, whereas the 3-year EFS rate of the patients who received HDCT was 
100%. No treatment-related mortality occurred during HDCT. 
Conclusion
Although the follow-up period was short and the patient cohort was small in size, the 
results of this study are encouraging. The limited toxicity and favorable EFS rate observed 
in children treated with reduced-dose CSRT followed by HDCT and ASCR warrant further 
exploration in a larger study population.
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INTRODUCTION
  The prognoses of high-risk medulloblastoma (MB) and 
supratentorial primitive neuroectodermal tumor (sPNET) are 
poor despite the combined use of chemotherapy and radio-
therapy [1, 2]. Although the 5-year event-free survival (EFS) 
rate for patients with average-risk MB or sPNET is 60-80% 
[3-5], the 5-year EFS rate for patients with high-risk MB 
or sPNET is 30-60% depending on the treatment received 
[1, 2]. Moreover, in cases with proven metastasis, the prog-
noses are worse. To improve the outcome of high-risk MB 
and sPNET, two obstacles that greatly affect the quality of 
life for patients, treatment-related mortality (TRM) and 
long-term sequelae, must be obviated. The currently avail-
able treatments for patients with high-risk MB or sPNET 
are plagued by considerable treatment-related toxicity due 
to the increased vulnerability of the central nervous system 
in young patients and radiation therapy-related significant 
long-term neurological sequelae [6-8]. All patients diagnosed 
with MB conventionally receive 36 Gy of craniospinal radia-
tion therapy (CSRT) with a boost of 18-20 Gy to the posterior 
fossa. Recently, reduced-dose CSRT with 23.4 Gy and a boost 
to the posterior fossa have been used for average-risk MB; 
however, 36 Gy of CSRT is still used for high-risk patients 
[5, 9, 10]. The fact that survivors of MB who received 23.4 
Gy instead of 36 Gy of CSRT experienced less severe neuro-
psychological toxicity prompted us to develop a strategy 
involving reduced-dose CSRT and intensified tandem 
high-dose chemotherapy with autologous stem cell rescue 
(HDCT/ASCR) [11]. Recently, we examined the efficacy and 
safety of tandem HDCT/ASCR for high-risk neuroblastoma 
based on the theory that dose escalation may improve surviv-
al, and we found improved survival rates [12, 13]. 
  Strother et al. [14] proposed HDCT/ASCR for the treatment 
of MB and sPNET, and their progression-free survival rates 
suggested that HDCT/ASCR is a feasible option for patients 
with average- and high-risk MB or sPNET. However, data 
showing the efficacy and long-term sequelae of HDCT/ASCR 
in children with high-risk brain tumors are limited.
  Thus, in this study, we prospectively investigated the ef-
fects of reduced-dose CSRT followed by tandem HDCT/ 
ASCR in children with a newly diagnosed high-risk MB 
or sPNET through a multicenter study with a single-arm 
regimen in an effort to reduce the incidence of long-term 
sequelae and improve survival.
MATERIALS AND METHODS
1. Patients
  Between March 2005 and April 2007, newly diagnosed 
high-risk MB and sPNET patients older than 3 years received 
treatment according to the Korean Society of Pediatric 
Neuro-Oncology (KSPNO) protocol S051 for high-risk brain 
tumors (Fig. 1) at the Samsung Medical Center, Asan Medical 
Center, Seoul National University Hospital, and Hanyang 
University Hospital, in Seoul, Korea. The patients were de-
fined as high-risk if they had metastatic disease at pre-
sentation (M+) or a residual tumor exceeding 1.5 cm
2 after 
surgery. 
  This study was approved by the institutional review board 
at each participating hospital. Written informed consent was 
obtained from the parents of each patient. 
2. Pre-HDCT chemotherapy and radiotherapy
  Initially, maximum resection of the tumor was attempted 
by a pediatric neurosurgeon at the participating centers. 
We defined the extent of resection using the neurosurgeons’ 
operative notes and magnetic resonance images (MRIs) ob-
tained after surgery. 
  The patients were scheduled to receive 2 cycles of pre-RT 
chemotherapy within 4 weeks after surgery. Cycle A con-
sisted of cisplatin (90 mg/m
2/day on day 0), etoposide (75 
mg/m
2/day on days 0-2), vincristine (1.5 mg/m
2/day on days 
0 and 7), and cyclophosphamide (1,500 mg/m
2/day on days 
1 and 2); cycle B consisted of carboplatin (300 mg/m
2/day 
on days 0 and 1), etoposide (75 mg/m
2/day on days 0-4), 
vincristine (1.5 mg/m
2/day on days 0 and 7), and ifosphamide 
(1,500 mg/m
2/day on days 0-4) (Table 1). Radiotherapy con-
sisted of 23.4 Gy (1.8 Gy per fraction, 5 fractions per week) 
to the craniospinal axis, with 30.6 Gy to the primary tumor. 
In cases with M2 or M3 stage disease, an additional 21.6 
Gy was applied to the seeding nodule. Within 4 weeks after 
RT, post-RT chemotherapy was initiated when the absolute 
neutrophil count exceeded 1,000/μL and the platelet count 
exceeded 75,000/μL. The patients were scheduled to receive 
cycles A and B alternating at 4-week intervals for 4 cycles 
(cycles A2, B2, A3, and B3). The doses used for post-RT 
chemotherapy were reduced to 75% of the pre-RT values, 
except for vincristine. After chemotherapeutic cycle B2, if 
the hematopoietic recovery was delayed for more than 2 
weeks, the doses used in cycles A3 and B3 were reduced 
to 50% of their pre-RT values, except for vincristine. After 
four cycles of post-RT chemotherapy, tandem HDCT/ASCR 
was performed (Fig. 1).
3. Collection of peripheral blood stem cells (PBSCs)
  Hematopoietic stem cells were collected from granulocyte- 
colony-stimulating factor-mobilized peripheral blood after 
cycle A1. We attempted to collect at least 2.0×10
6 CD34
+ 
cells/kg for tandem HDCT, and at least 1.0×10
6 CD34
+ cells/kg 
for each round of HDCT. If the collected PBSCs were not 
sufficient for tandem HDCT, we attempted to collect PBSCs 
again after cycle B1. 
4. HDCT with ASCR
  For the first round of HDCT (HDCT1), CTE (500 mg/ 
m
2/day carboplatin on days -8, -7, and -6; 300 mg/m
2/day 
thiotepa on days -5, -4, and -3; and 250 mg/m
2/day etoposide 
on days -5, -4, and -3) was used. Twelve weeks after day 
1 of HDCT1 and after recovery from organ failure, CM (1,500 
mg/m
2/day cyclophosphamide on days -8, -7, -6, and -5, 
and 60 mg/m
2/day melphalan on days -4, -3, and -2) was Korean J Hematol 2010;45:120-6.
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Table 1. Chemotherapeutic regimens.
Regimen Drug Dose Schedule
Cycle A Cisplatin      90 mg/m
2/day Day 0
Etoposide      75 mg/m
2/day Days 0-2
Vincristine     1.5 mg/m
2/day Days 0 and 7
Cyclophosphamide 1,500 mg/m
2/day Days 1 and 2
Cycle B Carboplatin    300 mg/m
2/day Days 0 and 1
Etoposide      75 mg/m
2/day Days 0-4
Vincristine     1.5 mg/m
2/day Days 0 and 7
Ifosphamide 1,500 mg/m
2/day Days 0-4
HDCT1 Carboplatin    500 mg/m
2/day Days -8, -7, and -6
Thiotepa    300 mg/m
2/day Days -5, -4, and -3
Etoposide    250 mg/m
2/day Days -5, -4, and -3
HDCT2 Cyclophosphamide 1,500 mg/m
2/day Days -8, -7, -6, and -5
Melphalan 60 mg/m
2/day Days -4, -3, and -2
Abbreviations: HDCT1, the first round of high-dose chemotherapy;
HDCT2, the second round of high-dose chemotherapy.
Fig. 1. Schema of the KSPNO-S051 protocol. PBSC, peripheral blood stem cell; CSRT, craniospinal radiotherapy; HDCT, high-dose chemotherapy; 
ASCR, autologous stem cell rescue.
given to the patients as a conditioning regimen for the second 
round of HDCT (HDCT2) (Table 1 and Fig. 1). After HDCT, 
autologous stem cells were infused on day 0 for marrow 
rescue.
5. Response and toxicity criteria
  The responses of the patients were categorized as follows: 
progressive disease (PD), ＞25% increase in tumor size or 
the appearance of a new tumor; stable disease (SD), ＜25% 
decrease or increase in tumor size; minor response (MR), 
25-50% decrease in tumor size; partial response (PR), ＞50% 
decrease in tumor size; or a complete response (CR), complete 
disappearance of all previously measurable tumors [15]. 
Relapse was defined as a lesion that developed at a new 
site (i.e., a site that was previously tumor free). MRIs were 
used to evaluate the disease status of all patients. Adverse 
events were evaluated according to the National Cancer 
Institute’s Common Toxicity Criteria (NCI-CTC).
6. Statistical analysis
  EFS was estimated from the date of the primary surgery 
to the date of relapse or disease progression or to the last 
follow-up date for those patients who did not experience 
any of these events. Overall survival (OS) was measured 
from the date of the primary surgery to the date of death 
for any cause or of the last follow-up. Kaplan-Meier estimates 
of the survival distribution were calculated and compared 
using the log-rank test. Variables were compared between 
groups using the chi-square test. Statistical significance was 
accepted for P-values＜0.05.
RESULTS
1. Patient characteristics
  Thirteen patients (9 boys and 4 girls) older than 3 years 
with a newly diagnosed MB (n=11) or sPNET (n=2) were 
enrolled. The median age at diagnosis was 95 months (range 
38-290). Seven patients (53.8%) had a residual tumor ＞1.5 
cm
2 after surgery. Ten patients (76.9%) had evidence of 
metastatic disease at diagnosis: 3 were stage M2, and 7 were 
stage M3 (Table 2). 
2. Response and outcome of HDCT with ASCR
  Of the 13 patients, 1 (No. 9) died from PD and another 
(No. 11) died from septic shock after cycle B2. Patient No. 
8, who relapsed after cycle B3, received RT followed by 
HDCT1 and HDCT2 and is currently alive. Ten patients 
received HDCT: eight received tandem treatment, whereas 
two patients received HDCT1 only because they refused 
further treatment. At the time of HDCT1, 7 patients were 
in CR and 3 in PR. In comparison, at the time of HDCT2, 
7 patients were in CR and 1 in SD. The median time from 
HDCT1 to the initiation of HDCT2 was 90.5 days (range 
82-99) (Table 2).
3. Hematologic recovery
  The median numbers of total nuclear cells and CD34
+ 
cells/kg infused for HDCT1 were 16.1×10
8 (range 2.8-20.92) 
and 36.1×10
6 (range 8.0-220.2), and for HDCT2 they were 
24.2×10
8 (range 3.1-48.9) and 33.9×10
6  (range 15.8-157.0), 
respectively.
  Hematologic recovery was achieved rapidly in all patients. 
The median time to neutrophil recovery was 8 days (range 
7-11) for HDCT1 and 9 days (range 8-10) for HDCT2; the 
median time required to reach a platelet count of 20,000/μL 
without transfusion for 7 days was 17 days (range 7-54) 
for HDCT1 and 20 days (range 9-21) for HDCT2.
4. Survival Rates
  The median follow-up duration was 39 months (range 
6-50). The probability of 3-year EFS for the 13 patients Korean J Hematol 2010;45:120-6.
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Table 2. Characteristics of the patients.
Patient
 no.
Sex/age 
(months)
Diagnosis M stage
Residual 
tumor 
> 1.5 cm
2
Time to event 
prior to HDCT 
(months)
Status at 
HDCT1
Status 
after 
HDCT2
Interval 
between 
HDCT1 and 
HDCT2 
(days)
EFS 
(months)
OS 
(months)
Current 
status
1 M/99 MB 2 No CR CR 92 50+ 50+
Alive 
(Ds-free)
2 M/139 MB 2 Yes PR SD 99 49+ 49+
Alive 
(Ds-free)
3 M/58 MB 2 Yes CR CR 95 46+ 46+
Alive 
(Ds-free)
4 M/84 MB 3 No CR CR 85 41+ 41+
Alive 
(Ds-free)
5 F/290 MB 3 No CR CR 82 39+ 39+
Alive 
(Ds-free)
6 M/105 MB 0 Yes CR CR 85 38+ 38+
Alive 
(Ds-free)
7 M/139 MB 0 Yes CR CR 89 34+ 34+
Alive 
(Ds-free)
8 F/220 MB 3 Yes 10
Off due to 
relapse
NA NA 9 48+
Alive 
(Ds-free)
a)
9M / 9 2M B 3 Y e s 6
Off due to 
progression
NA NA 6 16
Dead 
(with Ds)
10 F/94 sPNET 0 Yes PR NA NA 47+ 47+
Alive 
(Ds-free)
11 F/38 sPNET 3 No 10 NA NA NA 10 10
Dead 
(sepsis)
12 M/61 MB 3 No PR CR 95 33+ 33+
Alive 
(Ds-free)
13 M/95 MB 3 No CR NA NA 43+ 43+
Alive 
(Ds-free)
a)Alive and disease-free after RT and HDCT2.
Abbreviations: M, metastasis; HDCT1, first round of high-dose chemotherapy; HDCT2, second round of high-dose chemotherapy; EFS, 
event-free survival; OS, overall survival; MB, medulloblastoma; sPNET, supratentorial primitive neuroectodermal tumor; CR, complete 
response; PR, partial response; NA, not applicable; SD, stable disease; Ds, disease.
was 76.9±11.7%, whereas the 3-year OS was 84.6±10.0% 
(Fig. 2A). The 3-year EFS rate for those patients who actually 
received HDCT was 100%. The 3-year EFS rate for the Mo 
patients was 100%, whereas the rate for the M+ patients 
was 70.0±14.5% (Fig. 2B). One of the 11 patients was diag-
nosed with a MB relapsed, and another had PD prior to 
HDCT; hence, the 2-year EFS of the MB patients was 81.8± 
11.6%. Among the 9 patients with MB who received HDCT, 
8 received tandem double HDCT with ASCR, and none ex-
hibited a relapse or TRM. The 3-year EFS rate for the M0 
patients with MB was 100%, whereas the rate for the M+ 
patients at the time of diagnosis was 77.8±13.9% (Fig. 2C). 
One of the 2 sPNET patients received HDCT1; however, 
no further treatment was given based on the wishes of the 
parents, and another patient died of sepsis after chemo-
therapy cycle B2. 
5. Toxicity
  Ten (100%) and 7 (87.5%) patients suffered from a high 
fever (body temperature ≥38.5
oC) during HDCT1 and 
HDCT2, respectively. The incidence of a grade 3-4 fever, 
vomiting, diarrhea, veno-occlusive disease (VOD), hyper-
bilirubinemia, and elevations of liver enzymes during 
HDCT1 and HDCT2 is shown in Table 3. Of these, the 
most frequent toxicities were fever, stomatitis, and elevations 
of liver enzymes during HDCT1. More adverse events oc-
curred during HDCT1 than during HDCT2, but no TRM 
was observed (Table 3). 
DISCUSSION
  The clinical outcome for patients with a MB varies accord-
ing to age, tumor remnants, and metastatic stage [1, 16]; 
therefore, risk-adapted treatments are required to not only 
increase survival but to also reduce toxicity that can impact 
on a patient’s quality of life. Among pediatric brain tumors, 
MB has the greatest potential for extraneural spread. In pa-
tients with a metastatic (M2-3) MB, progression-free survival 
rates of 24-40% have been reported [17-19]. Although com-
bined treatment with chemotherapy and radiotherapy has 
improved the survival rate in recent years, a substantial num-
ber of patients have recurrent PD after multimodal treatment, 
including surgery, radiation, and chemotherapy [1-3]. Korean J Hematol 2010;45:120-6.
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Fig. 2. (A) The probability of 3-year overall survival (a) and event-free 
survival (EFS) (b) for the 13 patients were 84.6±10.0% and 76.9±11.7%, 
respectively. (B) The probability of 3-year EFS for the Mo (a) and M+ 
patients (b) was 100 and 70.0±14.5%, respectively. (C) The EFS for 
medulloblastoma patients with M0 (a) was 100%, whereas that for patients 
with M+ (b) at diagnosis was 77.8±13.9%. 
Table 3. Grade 3-4 toxicities during high-dose chemotherapy.
HDCT1   HDCT2 
(n=10) (n=8) P
N (%) N (%)
BT≥38.5ºC 10 (100) 7 (87.5) 0.264
Stomatitis   7 (70) 0 (0) 0.003
Vomiting   4 (40) 0 (0) 0.049
Diarrhea   5 (50) 1 (12.5) 0.103
Hyperbilirubinemia   4 (40) 1 (12.5) 0.049
Elevation of liver enzymes   6 (60) 1 (12.5) 0.046
Veno-occlusive disease   2 (20) 1 (12.5) 0.680
Treatment-related mortality   0 (0) 0 (0) 1.000
Abbreviations: HDCT1, the first round of high-dose chemotherapy;
HDCT2, the second round of high-dose chemotherapy.
Recently, HDCT with ASCR has been used to treat pediatric 
patients with advanced solid tumors or brain tumors and 
to avoid the deleterious side-effects of RT in infants and 
very young children with brain tumors [12, 15, 20]; however, 
few studies have demonstrated the utility of HDCT with 
ASCR in the front-line treatment of young children with 
high-risk MB or sPNET [14, 15, 20]. 
  A 10 Gy dose of CSRT could lead to a 10-point decrease 
in the intelligence quotient of the recipient and significantly 
increases the risk of growth hormone deficiency. Packer 
et al. [21] reported a growth hormone deficiency in all pa-
tients who received 36 Gy of CSRT and in 50% of patients 
who received 23.4 Gy. The extent to which RT could be 
decreased, in dose or volume, without a substantial increase 
in the disease relapse rate is unknown; thus, the CSRT dose 
should be reduced to the smallest dose that does not result 
in the relapse of the disease, and together with HDCT, could 
improve the OS and reduce the risk of RT-related cognitive 
and endocrine defects [20, 21]. Gajjar et al. [20] have shown 
a special interest in reducing the amount of chemotherapy 
not only in terms of dosage but also of duration. This phase 
II clinical trial used risk-adapted CSRT followed by a short, 
dose-intensive, cyclophosphamide-based regimen with seri-
al, autologous PBSC rescues, resulting in a 5-year EFS rate 
of 85% in average-risk patients and 70% in high-risk patients.  
  In our study, 23.4 Gy CSRT followed by tandem HDCT 
with ASCR was acceptable in terms of toxicity and the surviv-
al rate. The 3-year EFS rate for high-risk MB and sPNET 
patients was 76.9%. One patient had a relapse, another pa-
tient progressed before HDCT, and a third patient died of Korean J Hematol 2010;45:120-6.
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sepsis after chemotherapy; however, the 3-year EFS rate 
for those patients who actually received HDCT with ASCR 
was 100%. Compared with other studies of high-risk brain 
tumors, the EFS rate of our patients was encouraging, and 
no toxicity-related death occurred during tandem HDCT; 
however, the optimal therapy for patients with a relapse 
o r  P D  b e f o r e  H D C T  w i t h  A S CR should be investigated 
further. The patients who relapsed or progressed before 
HDCT with ASCR were older and had stage M3 disease 
at the time of diagnosis. Therefore, patients older than 6 
years of age or with M2-3 disease at presentation may need 
a higher dose CSRT (at least 30.6 Gy). 
  Carboplatin, etoposide, and thiotepa were used for HDCT1, 
whereas cyclophosphamide and melphalan were used for 
HDCT2 in this study. These regimens were tolerable, and 
no toxic death or relapse was observed after HDCT. Busulfan 
was avoided, as it might cause hepatic VOD. In a recent 
retrospective study, Cheuk et al. [22] speculated that for 
patients with a MB or sPNET, treatment with carboplatin 
and thiotepa or etoposide was among the safest and most 
effective regimens. The optimal combined regimen for con-
secutive tandem HDCT has yet to be determined for patients 
with high-risk brain tumors; however, we suggest that the 
use of different drug combinations between the first and 
second round of HDCT is a reasonable approach to avoid 
drug resistance and overlapping drug toxicities [15].
  It has been speculated that the second round of therapy 
i n  t a n d e m  H D C T  s h o u l d  b e  initiated soon after HDCT1 
to eradicate possible residual tumor cells and to prevent 
a relapse, and that delayed HDCT2 might be a cause of 
relapse [15]. However, in the present study, a high rate 
of adverse events occurred during HDCT1 compared to 
HDCT2; thus, sufficient rest was needed after HDCT1. The 
high rate of adverse events appeared to be related to differ-
ences in the intensities of the regimens, but no TRM occurred 
during tandem HDCT.
  In this study, the follow-up durations were too short to 
evaluate neurological sequelae or hormonal imbalances. The 
reduced-dose CSRT before HDCT with ASCR may have a 
favorable impact not only on survival but also on the patient’s 
quality of life, especially in terms of neurological function 
and hormonal balance. At present, we are conducting out-
come studies of neurological and hormonal functions in the 
long-term survivors of this study. 
  Although the follow-up period was short and the patient 
cohort was small in size, the results of this study are 
encouraging. The limited toxicity and favorable EFS rate 
observed in children treated with reduced-dose CSRT fol-
lowed by tandem HDCT and ASCR warrant further explora-
tion in a larger study population.
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